ClinicalTrials.gg
CompletedNCT04562116Updated Dec 5, 2024Results posted

A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic Dermatitis

A Phase 2 interventional study of Nemolizumab and CYP 450 Substrates in Atopic Dermatitis, sponsored by Galderma R&D. Completed at 6 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-05.

Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 2, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing nemolizumab in Dermatitis, Atopic — 3 open to participants now, 3 under way, 1 of them phase 3. nemolizumab · Dermatitis, Atopic.

Enrollment
12th of 14
17 · median 209
Started
2021
with 1 other
Phase 2
7 of 14
1 open now
Registered
8th of 14
by date
Lead sponsor
12 of 14
Galderma R&D

Among the 14 studies testing nemolizumab in Dermatitis, Atopic, this one is the 12th largest by enrollment, is one of 2 that started in 2021, is one of 7 in phase 2, and was the 8th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

3 of the 14 studies testing nemolizumab in Dermatitis, Atopic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About nemolizumab

nemolizumab: first FDA approval 2024 (NEMLUVIO), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing nemolizumab in Dermatitis, Atopic, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effect of nemolizumab (CD14152) on the pharmacokinetics (PK) of a drug "cocktail" representative of CYP450 (CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4/5 sensitive index substrates) in adult participants with moderate to- severe atopic dermatitis (AD).

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic atopic dermatitis (AD) for at least 2 years before the screening visit, and confirmed according to American Academy of Dermatology Consensus Criteria at the time of the screening visit
  • Eczema Area and Severity Index (EASI) score greater than or equal to (>=) 16 at both the screening and baseline visits
  • IGA score >= 3 (based on the Investigator's Global Assessment [IGA] scale ranging from 0 to 4, in which 3 is moderate and 4 is severe) at both the screening and baseline visits
  • AD involvement >=10 percent (%) of body surface area (BSA) at both the screening and baseline visits
  • Peak (maximum) pruritus numeric rating scale (PP NRS) score of at least 4.0 at both the screening and baseline visit
  • Documented recent history (within 6 months before the screening visit) of inadequate response to topical medications (topical [TCS] with or without topical calcineurin inhibitor [TCI])

Exclusion criteria

Exclusion Criteria:

  • Body weight less than (\<) 45 kilogram (kg)
  • Participants meeting 1 or more of the following criteria at screening or baseline: (a) Had an exacerbation of asthma requiring hospitalization in the preceding 12 months; (b) Reporting asthma that has not been well-controlled in the previous 3 months; (c) Asthma Control Test (ACT) \<= 19 (for those with a history of asthma); (d) Peak expiratory flow \< 80% of the predicted value
  • Participants with a current medical history of and/or chronic bronchitis
  • Cutaneous infection within 1 week prior to the baseline visit, any infection requiring treatment with oral or parenteral antibiotics, antivirals, antiparasitics or antifungals within 2 weeks prior to the baseline visit, or any confirmed or suspected coronavirus disease (COVID)-19 infection within 2 weeks before the screening or baseline visit. Participants may be rescreened once the infection has resolved. Resolution of COVID-19 infection can be confirmed by recovery assessment methods
  • Requiring rescue therapy for AD during the screening period or expected to require systemic rescue therapy during the treatment period
  • Positive serology results ( surface antigen [HBsAg] or hepatitis B core antibody [HBcAb], antibody, or antibody) at the screening visit
  • Treatment with systemic /immunomodulating drugs and/or systemic within 4 weeks prior to Screening
  • Known active or latent tuberculosis
  • Treatment with Biologics and their biosimilars within 8 weeks from Screening
  • Use of Phototherapy or tanning beds within 4 weeks from Screening
  • Use of medication known as inducer, inhibitor, or competitive substrate of one or more of the following cytochrome (CYP) enzymes: /5, CYP2C19, CYP2C9, CYD2D6, and CYP1A2 within 2 weeks from Screening
  • Treatment with Midazolam, Omeprazole, Warfarin Sodium, Metoprolol Tartrate within 2 weeks from Screening
  • History of or intolerance to CYP substrates and their
  • Participants for whom administration of the CYP substrates provided in this study is or medically inadvisable
  • Participants with (INR) > 1.5
  • Consumption of any 1 or more of the following food items and/or beverages within 1 week prior to baseline: Grapefruit or grapefruit juice, apple or apple juice, orange or orange juice, lemons or lemon juice, limes or lime juice, cranberries or cranberry juice; Vegetables from the mustard green family (eg, broccoli, kale); Charbroiled meats; Beverages, foods, or drugs containing caffeine
  • History of or current confounding skin condition
  • Current smokers
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 2
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    CYP 450 Substrates plus Nemolizumab

    Participants will receive 1 single oral dose of selected, commercially available, cytochrome P450 substrates (CYP450-S) on Day 1 and after a 1-week washout period, participants will receive a 60 milligram (mg) loading dose of nemolizumab via 2 consecutive subcutaneous (SC) 30-mg injections at the Week 1 visit, followed by a single 30-mg injection once in every 4 weeks (Q4W) at Week 5 and Week 9. Participants will receive a second oral dosing of CYP450-S at Week 10.

    Drug: Nemolizumab · Drug: CYP 450 Substrates

Interventions

  • Nemolizumab 30 mg will be administered as SC injections.

    Also known as: CD14152

  • DrugCYP 450 Substrates

    CYP substrates (Caffeine, Warfarin Sodium, Midazolam, Omeprazole, and Metoprolol Tartrate) will administered orally at Week 0 (Day 1) and Week 10 as per the commercially available prescribing information.

06

What researchers measure

Primary outcomes

  1. Change in Area Under the Concentration-time Curve From Time Zero to Infinity (AUC[0-infinity]) of Each of the 5 Probe Drugs Before and After 9-week Nemolizumab Treatment

    AUC (0-infinity) was defined as AUC from time 0 to infinity, calculated as the sum of AUC (0-last) and C(last)/lambda(z); where C(last) was the last observed measurable (non-BQL) concentration; and lambda(z) was apparent terminal elimination rate constant. Probe drugs included Caffeine, Metoprolol Tartrate, Midazolam, Omeprazole and Warfarin Sodium. Change in AUC(0-infinity) of each of the 5 probe drugs before (Baseline) and after 9-week nemolizumab treatment is reported.

    Time frame: Baseline (before nemolizumab injection, at Week 0) and Week 10 (after nemolizumab injection): Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 72 and 120 hours post-dose

  2. Change in Area Under the Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUC [0-last]) of Each of the 5 Probe Drugs Before and After 9-week Nemolizumab Treatment

    AUC (0-last) was defined as AUC from time 0 to the time of the last measurable (non-BQL) concentration, calculated by linear-linear trapezoidal summation. Probe drugs included Caffeine, Metoprolol Tartrate, Midazolam, Omeprazole and Warfarin Sodium. Change of AUC(0-last) of each of the 5 probe drugs before (Baseline) and after 9-week nemolizumab treatment is reported.

    Time frame: Baseline (before nemolizumab injection, at Week 0) and Week 10 (after nemolizumab injection): Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 72 and 120 hours post-dose

  3. Maximum Observed Plasma Concentration (Cmax) of Each of the 5 Probe Drugs Before and After 9-week Nemolizumab Treatment

    Cmax was defined as the maximum observed plasma concentration. Probe drugs included Caffeine, Metoprolol Tartrate, Midazolam, Omeprazole and Warfarin Sodium. Cmax of each of the 5 probe drugs before (Baseline) and after 9-week nemolizumab treatment is reported.

    Time frame: Baseline (before nemolizumab injection, at Week 0) and Week 10 (after nemolizumab injection): Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 72 and 120 hours post-dose

Secondary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs), AEs of Special Interest (AESIs), and Serious AEs (SAEs)

    An AE is defined as any untoward medical occurrence in a study participant administered a medicinal product which does not necessarily have a causal relationship with this treatment. SAE is any untoward medical occurrence that at any dose may results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product. A TEAE is defined as an AE that occurs on or after the first date of study drug(s) administration until the date of last study visit. An AESI is a noteworthy treatment-emergent event for the study drug that should be monitored closely and reported promptly.

    Time frame: Up to 24 weeks

07

Results

Posted Dec 5, 2024

Participant flow

The study was conducted at 2 sites in the United States and Bulgaria from 08 December 2021 to 07 June 2023.

Participant flow — Overall Study
MilestoneCYP 450 Substrates Plus Nemolizumab
Started17
Safety population16
Completed13
Not completed4
Withdrew: Lost to follow-up1
Withdrew: Withdrawal by subject3

Outcome measures

PrimaryChange in Area Under the Concentration-time Curve From Time Zero to Infinity (AUC[0-infinity]) of Each of the 5 Probe Drugs Before and After 9-week Nemolizumab Treatment

AUC (0-infinity) was defined as AUC from time 0 to infinity, calculated as the sum of AUC (0-last) and C(last)/lambda(z); where C(last) was the last observed measurable (non-BQL) concentration; and lambda(z) was apparent terminal elimination rate constant. Probe drugs included Caffeine, Metoprolol Tartrate, Midazolam, Omeprazole and Warfarin Sodium. Change in AUC(0-infinity) of each of the 5 probe drugs before (Baseline) and after 9-week nemolizumab treatment is reported.

Time frame:
Baseline (before nemolizumab injection, at Week 0) and Week 10 (after nemolizumab injection): Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 72 and 120 hours post-dose
Reported as:
Mean · hour*microgram per liter
Change in Area Under the Concentration-time Curve From Time Zero to Infinity (AUC[0-infinity]) of Each of the 5 Probe Drugs Before and After 9-week Nemolizumab Treatment
hour*microgram per literBefore Nemolizumab InjectionsAfter Nemolizumab Injections
Caffeine27064 ± 1680725281 ± 15146
Metoprolol Tartrate822 ± 698845 ± 792
Midazolam27.7 ± 1.6029.6 ± 15.0
Omeprazole932 ± 851976 ± 715
Warfarin Sodium20268 ± 526120399 ± 4153
Statistical analysis
  • Before Nemolizumab Injections vs After Nemolizumab Injections · Mixed Models Analysis · p = 0.5789 (A linear mixed-effect model was used to compare the natural log-transformed of the value, with substrate with or without Nemolizumab as the fixed effect and subject as a random effect.) · Ratio: 94.59 · 90% CI 79.57 to 112.45
  • Before Nemolizumab Injections vs After Nemolizumab Injections · Mixed Models Analysis · p = 0.9468 (A linear mixed-effect model was used to compare the natural log-transformed of the value, with substrate with or without Nemolizumab as the fixed effect and subject as a random effect.) · Ratio: 99.34 · 90% CI 83.66 to 117.96
  • Before Nemolizumab Injections vs After Nemolizumab Injections · Mixed Models Analysis · p = 0.1364 (A linear mixed-effect model was used to compare the natural log-transformed of the value, with substrate with or without Nemolizumab as the fixed effect and subject as a random effect.) · Ratio: 107.81 · 90% CI 99.14 to 117.24
  • Before Nemolizumab Injections vs After Nemolizumab Injections · Mixed Models Analysis · p = 0.1915 (A linear mixed-effect model was used to compare the natural log-transformed of the value, with substrate with or without Nemolizumab as the fixed effect and subject as a random effect.) · Ratio: 92.13 · 90% CI 82.85 to 102.44
  • Before Nemolizumab Injections vs After Nemolizumab Injections · Mixed Models Analysis · p = 0.5059 (A linear mixed-effect model was used to compare the natural log-transformed of the value, with substrate with or without Nemolizumab as the fixed effect and subject as a random effect.) · Ratio: 101.67 · 90% CI 97.41 to 106.12
PrimaryChange in Area Under the Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUC [0-last]) of Each of the 5 Probe Drugs Before and After 9-week Nemolizumab Treatment

AUC (0-last) was defined as AUC from time 0 to the time of the last measurable (non-BQL) concentration, calculated by linear-linear trapezoidal summation. Probe drugs included Caffeine, Metoprolol Tartrate, Midazolam, Omeprazole and Warfarin Sodium. Change of AUC(0-last) of each of the 5 probe drugs before (Baseline) and after 9-week nemolizumab treatment is reported.

Time frame:
Baseline (before nemolizumab injection, at Week 0) and Week 10 (after nemolizumab injection): Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 72 and 120 hours post-dose
Reported as:
Mean · hour*microgram per liter
Change in Area Under the Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUC [0-last]) of Each of the 5 Probe Drugs Before and After 9-week Nemolizumab Treatment
hour*microgram per literBefore Nemolizumab InjectionsAfter Nemolizumab Injections
Caffeine25294 ± 1563323805 ± 13334
Metoprolol Tartrate803 ± 666820 ± 742
Midazolam26.5 ± 12.428.5 ± 13.9
Omeprazole892 ± 825796 ± 718
Warfarin Sodium18034 ± 410018068 ± 3470
Statistical analysis
  • Before Nemolizumab Injections vs After Nemolizumab Injections · Mixed Models Analysis · p = 0.6665 (A linear mixed-effect model was used to compare the natural log-transformed of the value, with substrate with or without Nemolizumab as the fixed effect and subject as a random effect.) · Ratio: 95.82 · 90% CI 80.72 to 113.75
  • Before Nemolizumab Injections vs After Nemolizumab Injections · Mixed Models Analysis · p = 0.9316 (A linear mixed-effect model was used to compare the natural log-transformed of the value, with substrate with or without Nemolizumab as the fixed effect and subject as a random effect.) · Ratio: 99.15 · 90% CI 83.43 to 117.83
  • Before Nemolizumab Injections vs After Nemolizumab Injections · Mixed Models Analysis · p = 0.1371 (A linear mixed-effect model was used to compare the natural log-transformed of the value, with substrate with or without Nemolizumab as the fixed effect and subject as a random effect.) · Ratio: 107.75 · 90% CI 99.12 to 117.13
  • Before Nemolizumab Injections vs After Nemolizumab Injections · Mixed Models Analysis · p = 0.0962 (A linear mixed-effect model was used to compare the natural log-transformed of the value, with substrate with or without Nemolizumab as the fixed effect and subject as a random effect.) · Ratio: 88.66 · 90% CI 78.72 to 99.85
  • Before Nemolizumab Injections vs After Nemolizumab Injections · Mixed Models Analysis · p = 0.6807 (A linear mixed-effect model was used to compare the natural log-transformed of the value, with substrate with or without Nemolizumab as the fixed effect and subject as a random effect.) · Ratio: 100.81 · 90% CI 97.45 to 104.29
PrimaryMaximum Observed Plasma Concentration (Cmax) of Each of the 5 Probe Drugs Before and After 9-week Nemolizumab Treatment

Cmax was defined as the maximum observed plasma concentration. Probe drugs included Caffeine, Metoprolol Tartrate, Midazolam, Omeprazole and Warfarin Sodium. Cmax of each of the 5 probe drugs before (Baseline) and after 9-week nemolizumab treatment is reported.

Time frame:
Baseline (before nemolizumab injection, at Week 0) and Week 10 (after nemolizumab injection): Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 72 and 120 hours post-dose
Reported as:
Mean · micrograms per liter
Maximum Observed Plasma Concentration (Cmax) of Each of the 5 Probe Drugs Before and After 9-week Nemolizumab Treatment
micrograms per literBefore Nemolizumab InjectionsAfter Nemolizumab Injections
Caffeine3922 ± 15633688 ± 1512
Metoprolol Tartrate200 ± 131187 ± 114
Midazolam12.8 ± 5.3111.8 ± 4.09
Omeprazole374 ± 205349 ± 290
Warfarin Sodium695 ± 159651 ± 174
Statistical analysis
  • Before Nemolizumab Injections vs After Nemolizumab Injections · Mixed Models Analysis · p = 0.3431 (A linear mixed-effect model was used to compare the natural log-transformed of the value, with substrate with or without Nemolizumab as the fixed effect and subject as a random effect.) · Ratio: 91.22 · 90% CI 77.30 to 107.63
  • Before Nemolizumab Injections vs After Nemolizumab Injections · Mixed Models Analysis · p = 0.4277 (A linear mixed-effect model was used to compare the natural log-transformed of the value, with substrate with or without Nemolizumab as the fixed effect and subject as a random effect.) · Ratio: 91.05 · 90% CI 74.33 to 111.53
  • Before Nemolizumab Injections vs After Nemolizumab Injections · Mixed Models Analysis · p = 0.4963 (A linear mixed-effect model was used to compare the natural log-transformed of the value, with substrate with or without Nemolizumab as the fixed effect and subject as a random effect.) · Ratio: 94.79 · 90% CI 82.80 to 108.52
  • Before Nemolizumab Injections vs After Nemolizumab Injections · Mixed Models Analysis · p = 0.1931 (A linear mixed-effect model was used to compare the natural log-transformed of the value, with substrate with or without Nemolizumab as the fixed effect and subject as a random effect.) · Ratio: 88.24 · 90% CI 75.08 to 103.70
  • Before Nemolizumab Injections vs After Nemolizumab Injections · Mixed Models Analysis · p = 0.2960 (A linear mixed-effect model was used to compare the natural log-transformed of the value, with substrate with or without Nemolizumab as the fixed effect and subject as a random effect.) · Ratio: 92.94 · 90% CI 82.51 to 104.69
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs), AEs of Special Interest (AESIs), and Serious AEs (SAEs)

An AE is defined as any untoward medical occurrence in a study participant administered a medicinal product which does not necessarily have a causal relationship with this treatment. SAE is any untoward medical occurrence that at any dose may results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product. A TEAE is defined as an AE that occurs on or after the first date of study drug(s) administration until the date of last study visit. An AESI is a noteworthy treatment-emergent event for the study drug that should be monitored closely and reported promptly.

Time frame:
Up to 24 weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs), AEs of Special Interest (AESIs), and Serious AEs (SAEs)
ParticipantsCYP 450 Substrates Plus Nemolizumab
TEAEs0
AESIs0
SAEs0

Adverse events

Collected over Up to 24 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CYP 450 Substrates Plus Nemolizumab0/16 (0%)0/16 (0%)0/16 (0%)

Baseline characteristics

Enrolled population included all participants who signed the informed consent form and are enrolled in the study.

Age, Continuous
Age, Continuous(years)CYP 450 Substrates Plus Nemolizumab
Mean47.0 ± 7.64
Sex: Female, Male
Sex: Female, Male(Participants)CYP 450 Substrates Plus Nemolizumab
Female7
Male10
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)CYP 450 Substrates Plus Nemolizumab
Hispanic or Latino0
Not Hispanic or Latino17
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CYP 450 Substrates Plus Nemolizumab
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White17
More than one race0
Unknown or Not Reported0
08

Study locations

6 sites
  • 8894 Galderma Investigational Site
    North Hollywood, California 91606, United States
  • 9954 Galderma Investigational Site
    Hallandale Beach, Florida 33009, United States
  • 9923 Galderma Investigational Site
    Miami, Florida 33147, United States
  • 8030 Galderma Investigational Site
    Raleigh, North Carolina 27612, United States
  • 8076 Galderma Investigational Site
    Austin, Texas 78759, United States
  • 5952 Galderma Investigational Site
    Sofia, 1612, Bulgaria
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Jun 2023, 17 months.

Results were first posted in Dec 2024, 1 year 5 months after primary completion. A results delay was requested in Apr 2024.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 17 months is above that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2020
First posted
Sep 24, 2020
StartActual
Dec 8, 2021
Primary completionActual
Jun 7, 2023
CompletionActual
Jun 7, 2023
Results delay requested
Apr 24, 2024
Results first posted
Dec 5, 2024
Last update
Dec 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04562116
Lead sponsor
Galderma R&D
Responsible party
Sponsor
First posted
Sep 24, 2020
Start date
Dec 8, 2021
Primary completion
Jun 7, 2023
Completion
Jun 7, 2023
Results posted
Dec 5, 2024
Last update
Dec 5, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nemolizumab

Start the discussion